AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02238340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dipirone
Study NCT02140762 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenABCWY
Description: Subjects received one dose of 0.5 mL MenABCWY vaccine (intramuscular (IM) injection) at day 1 and a second dose after 2 months.
Study NCT02140762 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 0.5 mL saline solution (IM)
Study NCT02140762 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MenACWY
Description: Subjects received one dose of 0.5 mL placebo (IM) at day 1 and one dose of 0.5 mL MenACWY vaccine (IM) after 2 months.
Study NCT02227901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipifarnib
Description: Given PO
Study NCT02227901 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo EBRT
Study NCT02227901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study NCT02227901 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01711333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pletaal SR capsule
Description: two capsules once a day of Pletaal SR 100mg Capsules
Study NCT04050540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: 200 mg of doxycycline to be taken orally within 24 hours and up to 72 hours after each condomless sex act
Study NCT04454840 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasma from healthy young people treatment + Riluzole
Description: Intravenous injection: the subjects received 400ml of intravenous plasma infusion every 2 weeks, with a continuous course of 2 treatments and a course of treatment every 3 months. The course of treatment lasted 10 months, with a total of 3200ml of plasma infusion.
Study NCT04454840 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riluzole
Description: The basic treatment is Riluzole 25\~50mg twice daily
Study NCT00545740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD476 (1.2g)
Description: 1.2g SPD476 once daily (QD) orally
Study NCT01973595 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No Almonds, Then almonds
Description: No almonds will be consumed by participants for 3 weeks.
Study NCT05972148 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Digital scanning
Description: Five intraoral scans, one for each arch before the insertion of scanbodies, were obtained. The implant locations were then marked, and the software trimmed a 6mm diameter circular section of the scan from the implant locations to allow the scanbodies to be added. Abutment-level polyetheretherketone (PEEK) scanbodies were hand-tightened onto each implant and not moved for the remainder of the scans. Scanbodies were scanned using a circular scan path, and scanning was finalized.
Study NCT05972148 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photogrammetry
Description: Rectangular-shaped titanium photogrammetry scanbodies were hand-tightened onto the Implants. Scanbodies were not moved before completing all scans for each arch. A total of five scans of each arch were obtained using a photogrammetry device. Measurements were successfully recorded by turning them green on the computer screen.
Study NCT02201277 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Filter Placed
Study NCT03486665 — intervention group
Intervention type: OTHER
Intervention: Blood Sampling
Description: Blood samples will be taken from all patients and healthy volunteers.
Study NCT03486665 — intervention group
Intervention type: OTHER
Intervention: CSF Sampling
Description: CSF sample will be taken from hospitalized newly diagnosed patients only.
Study NCT03576079 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser therapy
Description: epic model biolase with an output of 4W, 1800 J wavelength with a continuous Laser mode.
Study NCT03576079 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: anterior re-positioning splint
Description: hard acrylic anterior re-positioning splint
Study NCT03576079 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: inactive Laser therapy
Description: sham Laser, with inactive beam
Study NCT02466685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-18038683
Description: JNJ-18038683 10-20 mg/day tablet for 8 weeks
Study NCT02466685 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablet daily
Study NCT03777163 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Butantan Institute Trivalent Seasonal Influenza Vaccine
Description: Butantan Institute and Pasteur-Mérieux (present, Sanofi Pasteur) established a technology transfer in 1999 for the production of a trivalent influenza vaccine of inactivated split-virion using embryonated eggs. The technology transfer followed a progressive approach from importing the finished product, to packaging and quality control test for release (1999), and, finally, to the first batch of influenza vaccine entirely produced by Butantan (2011). In 2013, the Butantan vaccine was registered by the Brazilian National Agency of Sanitary Surveillance (ANVISA).
Study NCT00989118 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser treatment of ovarian endometrioma
Description: Laser vaporization of ovarian endometrioma
Study NCT00989118 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser treatment of ovarian endometrioma
Description: Laser vaporization of ovarian endometrioma
Study NCT03773497 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Common Snack Combination
Description: Combination of Chips, Pretzels, and Popcorn.
Study NCT03773497 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cheesy Broccoli Snack
Description: Oven-roasted, freeze-dried, cheese flavored broccoli
Study NCT03773497 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cheesy Broccoli with Daikon Radish Snack
Description: Oven-roasted, freeze-dried, cheese flavored broccoli with Daikon radish powder
Study NCT03773497 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Uncooked Broccoli Snack
Description: Uncooked, freeze-dried broccoli with ranch-type dip
Study NCT03681132 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Stop of therapy
Description: The active intervention is to stop antiviral therapy, and delay re-start in the high-threshold group.
Study NCT03692845 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transforaminal Lumbar Interbody Fusion either open or minimally invasive
Description: Spinal fusion procedure through the intervertebral foramen
Study NCT03777163 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Sanofi Trivalent Seasonal Influenza Vaccine
Description: VAXIGRIP® was launched in 1968 and since then has been licensed in more than 100 countries and prequalified by WHO in 2011. Several clinical studies by Sanofi Pasteur have examined the safety and immunogenicity of Vaxigrip® in older children (8-10 years), adults (18-59 years), elderly (> 60 years),11,12 children (six months to three years) 13 and pregnant women.
Study NCT05968417 — intervention group
Intervention type: OTHER
Intervention: Observational study - sample collection only.
Description: No intervention - blood and/or bone marrow sample collection only
Study NCT02234219 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Heart-shape anastomosis
Description: a new operation approach for Hirschsprung disease
Study NCT02234219 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Soave anastomosis
Description: traditional approach for Hirschsprung disease
Study NCT01658501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg PB1023
Study NCT01658501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 70 mg PB1023
Study NCT01658501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg PB1023
Study NCT01658501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (0.9% Sodium Chloride)
Study NCT02238340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexametasone
Study NCT02238340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine IV (rescue)
Study NCT04787068 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupational Therapy support
Description: Intervention include (a) didactic education about diseases; (b) the use of errorless techniques to improve assistance for CR's Activities of Daily Living (ADL), Instrumental ADL, and communication tasks; (c) the use of incentives (e.g., providing a favorite scented shampoo); (e) use of a schedule/calendar on a computer, cell phone and/or blackboard in CR's home to coordinate caregiving tasks for family members; (f) suggesting more frequent PACE daycare visits or use of a nearby PACE, having a snack or short game to prevent going to bed right after dinner); (d) use of the Buffalo Functional Exercise for strengthening ( a home-based exercise developed for PACE by the PI and shown to be effective in preventing falls)
Study NCT04159363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: An interactive Colorectal Cancer self-Management enhancement smartphone-based psychosocial intervention programme (iCanManage)
Description: The iCanManage consists of two components: (1a) Existing functions from the BuddyCare mobile application that provide a comprehensive 29 day-by-day perioperative guide for patients who will be undergoing colorectal elective surgery; (1b) a dashboard for healthcare professionals to monitor patients and their caregivers' well-being as well as allow mutual communication; and (2) Newly developed digitalised psychosocial content (e.g., mindfulness-based activities with audio cover, video materials related to positive psychology, patient ambassadors' success stories and relevant psychoeducation) tailored for colorectal cancer patients and caregivers, with the aim of providing them emotional and psychosocial support.
Study NCT02659553 — intervention group
Intervention type: PROCEDURE
Intervention: steatosis
Description: Liver Transplantation with graft steatosis
Study NCT00866671 — intervention group
Intervention type: DRUG
Intervention: nelarabine
Description: Nelarabine is a prodrug of 9-β-D-arabinofuranosylguanine (ara-G), a deoxyguanosine analogue.
Study NCT01811576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TV-1106
Study NCT01811576 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human growth hormone
Description: Subcutaneous once daily
Study NCT06184841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAIC combined with intravenous PD-1
Description: Hepatic arterial chemoinfusion (HAIC) was used for interventional therapy with at least 2 cycles of hepatic arterial infusion. The intervention was started with sintilimab at the same time, 200mg each time, and the drug was repeated every 3 weeks.
Study NCT04159532 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MAG-EPA/MAG-DHA
Description: monoglyceride of eicosapentaenoic acid and docosahexaenoic acid in proportion of 460:200
Study NCT04159532 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: TG-EPA/TG-DHA
Description: Triglyceride of eicosapentaenoic acid and docosahexaenoic acid in proportion of 460:200
Study NCT04159532 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EE-EPA/EE-DHA
Description: Ethyl ester of eicosapentaenoic acid and docosahexaenoic acid in proportion of 460:200
Study NCT01460407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684
Description: Administered orally
Study NCT01460407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Administered orally
Study NCT03301064 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy and Strengths Based Case Management (MET/SBCM)
Description: Key objectives of the intervention are as follows: (1) identify health and personal goals and develop discrepancies between goals and current actions, (2) provide feedback related to risks associated with the participant's drinking (e.g., driving after drinking, liver disease), (3) provide normative feedback about the participant's pattern of drinking to alcohol use in the US among Latinos in the participant's age and gender group, (4) discuss reasons for drinking (e.g., feeling isolated from family, machismo, low status employment), (5) weigh the pros and cons of drinking and reasons to reduce drinking (e.g., to better provide for the family, improving family relationships), (6) negotiate a plan for reducing drinking and/or seeking help, (7) recognize personal strengths in the process of change (e.g., religiosity, desire to provide for family), and (8) identify needed social and health services and explore potential barriers (e.g., transportation).
Study NCT03301064 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol education brochure
Description: The alcohol education brochure will address health risks associated with alcohol use and will provide information on low-risk drinking.
Study NCT03301064 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol education brochure
Description: The alcohol education brochure will address health risks associated with alcohol use and will provide information on low-risk drinking.
Study NCT00612625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glucagon-like peptide-1
Description: continuous infusion of GLP-1 (1½ pmol/kg/min)
Study NCT00612625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: continuous infusion of saline
Study NCT04911712 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: a hospital formula of normal protein liquid diet supplementation
Description: group 1 (control group) who will get a hospital formula of normal protein liquid diet supplementation (40 grams per 1000 mL)
Study NCT04911712 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: a hospital formula of high protein liquid food supplementation
Description: group 2 (intervention group) will get a hospital formula of high protein liquid food supplementation (60 grams per 1000 mL) as much as 2 bottles (each bottle contains 200 mL)
Study NCT03675542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CUDC-305
Description: Dose-selection treatment with HSP90 inhibitor (CUDU-305)
Study NCT03419390 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: combined Coaxial Optical Coherence Tomography (OCT) System
Description: The investigational device is an OCT scanner prototype with two different wavelengths developed based on a CE marked OCT device (Spectralis® Heidelberg) at the Berner Fachhochschule, Biel
Study NCT01107561 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Seldinger technique
Description: Involves blind needle insertion through the skin into the cricoid membrane followed by insertion of the guide-wire and subsequent insertion of the tube over the guidewire
Study NCT01107561 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Airway Approach
Description: The classical open or surgical technique involves a vertical skin incision with blunt dissection and identification of the anatomy followed by incision of the cricoid membrane and tube insertion.
Study NCT04868487 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Literacy Education
Description: Health literacy education, consisting of four sessions, was given to the intervention group.
Study NCT02385916 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: EstroSense®/MD
Description: A natural product already approved by Health Canada
Study NCT02385916 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT00844805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Study NCT00844805 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00844805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Study NCT00844805 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Naproxen
Study NCT04557787 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SpeediCath® Standard female
Description: Intermittent catheterization through the urethra draining the bladder, using SpeediCath® Standard female.
Study NCT04557787 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New intermittent Variant 1 catheter for females
Description: Intermittent catheterization through the urethra draining the bladder, using the new Variant 1 catheter.
Study NCT04557787 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New intermittent Variant 2 catheter for females
Description: Intermittent catheterization through the urethra draining the bladder, using the new Variant 2 catheter.
Study NCT00857948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ivermectin treatment conditioner
Description: Application followed by thorough rinsing of the hair and scalp with water.
Study NCT00857948 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, vehicle control
Description: Application followed by thorough rinsing of the hair and scalp with water.
Study NCT01287377 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Counseling
Description: Telephone counseling has several distinguishing features, namely proactive follow up counseling calls, a manualized protocol, and relapse-sensitive scheduling. The follow-up call schedule includes a reminder call if the quit date is more than one week out, a call within 24 hours of the quit attempt, another call 4-7 days after the quit date, and another call 10-14 days after the quit date.
Study NCT01287377 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Counseling
Description: Telephone counseling has several distinguishing features, namely proactive follow up counseling calls, a manualized protocol, and relapse-sensitive scheduling. The follow-up call schedule includes a reminder call if the quit date is more than one week out, a call within 24 hours of the quit attempt, another call 4-7 days after the quit date, and another call 10-14 days after the quit date.
Study NCT01287377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Patches
Description: Subjects are randomized into one of these pharmacotherapy interventions: direct mailing of active patches with a message to start using it on their quit date, direct mailing of active patches with a message to start using it right away, or usual care patches in which no patches are sent directly (although clients may still get them through their usual channels).~For those in the usual care condition, patches will not be mailed directly to them; however, we will facilitate their use by providing a certificate that can be used by the State Medicaid program and some other insurance companies to obtain free patches. For those in the active condition, we will mail 2 weeks of patches directly to their home. All subjects will receive a 2 week starter kit with fourteen 21mg patches.
Study NCT01287377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patches
Description: Subjects are randomized into one of these pharmacotherapy interventions: direct mailing of active patches with a message to start using it on their quit date, direct mailing of active patches with a message to start using it right away, or usual care patches in which no patches are sent directly (although clients may still get them through their usual channels).~For those in the usual care condition, patches will not be mailed directly to them; however, we will facilitate their use by providing a certificate that can be used by the State Medicaid program and some other insurance companies to obtain free patches. For those in the active condition, we will mail 2 weeks of patches directly to their home. All subjects will receive a 2 week starter kit with fourteen 21mg patches.
Study NCT03738384 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Knee Connect + Visual Feedback System
Description: A device to measure knee angle. It sends data a smartphone or tablet to be displayed as part of a visual feedback system.
Study NCT00545740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD476 (2.4 g)
Description: 2.4g SPD476 QD orally
Study NCT00545740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD476 (4.8 g)
Description: 4.8g SPD476 QD orally
Study NCT01658501 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (0.9% Sodium Chloride)
Study NCT01012206 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention regarding food habits and physical activity.
Description: Children in the intervention group participated in an intervention program regarding food habits and physical activity.
Study NCT03710239 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dilapan-S
Description: Synthetic osmotic dilator
Study NCT03710239 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laminaria
Description: Seaweed-based osmotic dilator
Study NCT01889134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sedron (alendronate)
Study NCT01889134 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Parathyroidectomy